Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 16;22(4):1929.
doi: 10.3390/ijms22041929.

Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?

Daniela Mokra  1 , Juraj Mokry  2
Affiliations
Review

Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?

Daniela Mokra et al. Int J Mol Sci. .

Abstract

Despite progress in understanding the pathophysiology of acute lung damage, currently approved treatment possibilities are limited to lung-protective ventilation, prone positioning, and supportive interventions. Various pharmacological approaches have also been tested, with neuromuscular blockers and corticosteroids considered as the most promising. However, inhibitors of phosphodiesterases (PDEs) also exert a broad spectrum of favorable effects potentially beneficial in acute lung damage. This article reviews pharmacological action and therapeutical potential of nonselective and selective PDE inhibitors and summarizes the results from available studies focused on the use of PDE inhibitors in animal models and clinical studies, including their adverse effects. The data suggest that xanthines as representatives of nonselective PDE inhibitors may reduce acute lung damage, and decrease mortality and length of hospital stay. Various (selective) PDE3, PDE4, and PDE5 inhibitors have also demonstrated stabilization of the pulmonary epithelial-endothelial barrier and reduction the sepsis- and inflammation-increased microvascular permeability, and suppression of the production of inflammatory mediators, which finally resulted in improved oxygenation and ventilatory parameters. However, the current lack of sufficient clinical evidence limits their recommendation for a broader use. A separate chapter focuses on involvement of cyclic adenosine monophosphate (cAMP) and PDE-related changes in its metabolism in association with coronavirus disease 2019 (COVID-19). The chapter illuminates perspectives of the use of PDE inhibitors as an add-on treatment based on actual experimental and clinical trials with preliminary data suggesting their potential benefit.

Keywords: COVID-19; acute lung injury; acute respiratory distress syndrome; animal models; phosphodiesterase inhibitors; sepsis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bernard G.R., Artigas A., Brigham K.L., Carlet J., Falke K., Hudson L., Lamy M., Legall J.R., Morris A., Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordi-nation. Am. J. Respir. Crit. Care Med. 1994;149:818–824. doi: 10.1164/ajrccm.149.3.7509706. - DOI - PubMed
    1. ARDS Definition Task Force. Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D., Caldwell E., Fan E., Campo-rota L., Slutsky A.S. Acute respiratory distress syndrome: The Berlin Definition. JAMA. 2012;307:2526–2533. - PubMed
    1. Seeley E.J. Updates in the Management of Acute Lung Injury: A Focus on the Overlap Between AKI and ARDS. Adv. Chronic Kidney Dis. 2013;20:14–20. doi: 10.1053/j.ackd.2012.10.001. - DOI - PubMed
    1. Rubenfeld G.D., Caldwell E., Peabody E., Weaver J., Martin D.P., Neff M., Stern E.J., Hudson L.D. Incidence and Outcomes of Acute Lung Injury. New Engl. J. Med. 2005;353:1685–1693. doi: 10.1056/NEJMoa050333. - DOI - PubMed
    1. Bellani G., Laffey J.G., Pham T., Fan E., Brochard L., Esteban A., Gattinoni L., Van Haren F., Larsson A., McAuley D.F., et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315:788–800. doi: 10.1001/jama.2016.0291. - DOI - PubMed

MeSH terms

LinkOut - more resources